Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Year in review

Accelerating Revenue Cycle Performance in the Healthcare Industry

Michael Duke, Principal Healthcare Consultant at Baker Tilly US, discusses the importance of data and analytics for internal audits, organizational risk reduction, workflow automation, and to drive value in healthcare....

Impetus Digital

- PMLiVE

Valneva strikes European COVID-19 vaccine deal

The European Union intends to purchase up to 60 million doses of Valneva’s its inactivated COVID-19 vaccine VLA2001 by the end of 2023

- PMLiVE

Moderna clashes with US government over COVID-19 vaccine

A year-long wrangle with the US government over who invented a core component of the Moderna COVID-19 vaccine could have far-reaching implications

regeneron headquarters

Regeneron’s antibody cocktail REGEN-COV offers sustained protection against COVID-19

The drug is shown to give sustained protection against COVID-19, cutting the risk of infection by more than 80% for up to eight months

- PMLiVE

Pfizer’s oral antiviral Paxlovid significantly cuts risk of severe COVID-19

Pfizer has halted its phase 2/3 trial of its new antiviral combo Paxlovid after analysis shows it cuts the risk of hospitalisation or death from COVID-19 by nearly 90%

- PMLiVE

UK’s MHRA approves first oral antiviral against COVID-19

Merck's Lagevrio has been approved for people with mild to moderate COVID-19 and at least one risk factor for developing severe illness

Data-driven healthcare communications

Data analysis is everywhere, and the role it plays in our lives is increasing exponentially. From deciding what car to purchase to what medicine will be prescribed for us, the...

Lucid Group Communications Limited

- PMLiVE

Gilead sales rise by 13%, buoyed by anti-COVID-19 drug Veklury

The company has had a ‘very strong’ third quarter in spite of a sharp decline in its HIV portfolio due to generic competition

Top 10 benefits of virtual advisory boards

Why virtual advisory boards should be part of every brand's toolbox in the post-COVID new normal.

Impetus Digital

- PMLiVE

Eli Lilly focuses on 2022 launches as revenues climb by 18%

Revenues in the third quarter of 2021 were driven by volume growth in new medicines, but earnings per share were a fraction below analysts’ predictions

- PMLiVE

Merck’s COVID-19 antiviral under review in Europe by EMA

Molnupiravir could be the first oral antiviral treatment for COVID-19 in Europe for patients at risk of severe disease

- PMLiVE

Pfizer-BioNTech booster offers 95.6% efficacy against COVID-19

Results from the world’s first randomised, controlled COVID-19 vaccine booster trial show a third dose of Pfizer-BioNTech’s Comirnaty offers near-total protection from infection

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links